OncoBEAMTM

Revolutionary liquid biopsy technology

OncoBEAM

Our OncoBEAM™ technology set the gold standard for ctDNA-based liquid biopsy testing as the first liquid biopsy technology used for oncology studies. It’s the most sensitive digital PCR approach available today. Proven to detect important mutations from 0.02% to 0.04% allele frequency, OncoBEAM technology ensures reliable molecular information for real-time monitoring of tumor response and subsequent therapy interventions.

Based on BEAMing (Bead, Emulsion, Amplification, and Magnetics), OncoBEAM combines emulsion digital PCR with magnetic beads and flow cytometry for highly sensitive detection and quantification of mutant tumor DNA molecules.

  1. 2003:

    OncoBEAM is first described in a study.1

  2. 2008:

    The field of liquid biopsy was birthed when investigators at Johns Hopkins School of Medicine successfully demonstrated the clinical utility of OncoBEAM in a landmark study of metastatic colorectal cancer patients.2

  3. 2009-2020:

    Nearly 100 peer-reviewed publications, more than 200 posters and publications, and at least 30 drugs have been developed using OncoBEAM technology.

Citations

1. Dressman D, Yan H, Traverso G, Kinzler KW, Vogelstein B. Transforming single DNA molecules into fluorescent magnetic particles for detection and enumeration of genetic variations. Proc Natl Acad Sci U S A. 2003 Jul 22;100(15):8817-22. doi: 10.1073/pnas.1133470100. Epub 2003 Jul 11. PMID: 12857956; PMCID: PMC166396.

2. https://pubmed.ncbi.nlm.nih.gov/18670422/

Tumor-specific tests

Tumor Specific Tests

AML

GenesExonsCodon(s)Mutations (Nucleotide Change)
IDH14132R132S [394C>A], R132G [394C>G], R132C [394C>T], R132H [395G>A], R132L [395G>T]
IDH24a140R140W [418C>T], R140Q [419G>A], R140L [419G>T]
4b172R172K [515G>A], R172M [515G>T]

Breast

GenesExonsCodon(s)Mutations (Nucleotide Change)
AKT1217E17K [49G>A]
ESR15380E380Q [1138G>C]
7463S463P [1387T>C]
8534, 535, 536, 537, 538V534E [1601T>A], P535H [1604C>A], L536H [1607T>A], L536P [1607T>C], L536R [1607T>G], L536Q [1607_1608delinsAG], Y537N [1609T>A], Y537S [1610A>C], Y537C [1610A>G], D538G [1613A>G]
PIK3CA7420C420R [1258T>C]
9542, 545, 546E542K [1624G>A], E545G [1634A>G], E545K [1633G>A], Q546K [1636C>A]
201043, 1047M1043I [3129G>T], H1047R [3140A>G], H1047L [3140A>T], H1047Y [3139C>T]

Colorectal

Additional mutations are available in PIK3CA(10,20)/AKT1(2)/ BRAF(15). For detailed information contact your local key Account Manager or drop us a line via info@sysmex-inostics.com

GenesExonsCodon(s)Mutations (Nucleotide Change)
KRAS212,13G12S [34G>A], G12R [34G>C], G12C [34G>T], G12D [35G>A], G12A [35G>C], G12V [35G>T], G13D [38G>A]
359, 61A59T [175G>A], Q61H [183A>C, 183A>T], Q61L [182A>T]
4117, 146K117N [351A>C, 351A>T], A146T [436G>A], A146V [437C>T]
NRAS212,13G12S [34G>A], G12R [34G>C], G12C [34G>T], G12D [35G>A], G12A [35G>C], G12V [35G>T], G13R [37G>C], G13D [38G>A], G13V [38G>T]
359, 61A59T [175G>A], Q61H [183A>C, 183A>T], Q61R [182A>G], Q61L [182A>T], Q61K [181C>A]
4117, 146K117N [351C>A, 351A>T], A146T [436G>A]
BRAF15600V600E [1799T>A]
PIK3CA10542, 545, 546E542K [1624G>A],E545G [1633G>A], E545K [1634A>G], Q546K [1636C>A]
201043, 1047M1043I [3129G>T], H1047R [3140A>G], H1047L[3140A>T], H1047Y[3139C>T]
AKT1217E17K [49G>A]
BRAF15600V600K [1798_1799delinsAA]

Giloma

GenesExonsCodon(s)Mutations (Nucleotide Change)
IDH14132R132S [394C>A], R132G [394C>G], R132C [394C>T], R132H [395G>A], R132L [395G>T]
IDH24a140R140W [418C>T], R140Q [419G>A], R140L [419G>T]
4b172R172K [515G>A], R172M [515G>T]

Lung

GenesExonsCodon(s)Mutations (Nucleotide Change)
BRAF15600V600E [1799T>A]
EGFR19746, 747E746_A750del [2235_2249del, 2236_2250del], E746_S752>V [2237_2255delinsT], L747_A750>P [2239_2248delinsC], L747_T751del [2240_2254del], L747_P753>S [2240_2257del]
20790, 797T790M [2369C>T], C797S [2389T>A, 2390G>C]
21858, 861L858R [2573T>G], L861Q [2582T>A]
KRAS212, 13G12S [34G>A], G12R [34G>C], G12C [34G>T], G12D[35G>A], G12A [35G>C], G12V [35G>T], G13D [38G>A]
361Q61L [182A>T], Q61H [183A>T, 183A>C]

Melanoma

GenesExonsCodon(s)Mutations (Nucleotide Change)
BRAF15600V600E [1799T>A], V600K [1798_1799delinsAA]
NRAS361Q61H [183A>C, 183A>T], Q61R [182A>G], Q61L [182A>T], Q61K [181C>A]

Pancreatic

GenesExonsCodon(s)Mutations (Nucleotide Change)
KRAS212,13G12S [34G>A], G12R [34G>C], G12C [34G>T], G12D [35G>A], G12A [35G>C], G12V [35G>T], G13D [38G>A]
359, 61A59T [175G>A], Q61H [183A>C, 183A>T], Q61L [182A>T]
4117, 146K117N [351A>C, 351A>T], A146T [436G>A], A146V [437G>T]
NRAS212,13G12S [34G>A], G12R [34G>C], G12C [34G>T], G12D [35G>A], G12A [35G>C], G12V [35G>T], G13R [37G>C], G13D [38G>A], G13V [38G>T]
359, 61A59T [175G>A], Q61H [183A>C, 183A>T], Q61R [182A>G], Q61L [182A>T], Q61K [181C>A]
4117,146K117N [351C>A, 351A>T], A146T [436G>A]

Prostate

GenesExonsCodon(s)Mutations (Nucleotide Change)
AR4702, 716L702H [2105T>A], L702Q [2104_2106delinsACC, 2104_2106delinsACG, 2104_2106delinsACT, 2104_2106delinsACA], V716M [2148G>A]
5742W742L [2225G>T], W742C [2226G>T]
8875, 877, 878, 896H875Y [2623C>T], F877L [2629T>C, 2631C>A, 2631C>G], T878A [2632A>G], T878S [2633C>G], M896V [2686A>G], M896T [2687T>C]

The video below illustrates the main steps of the BEAMing process

  1. PCR amplification

  2. Formation of water-in-oil emulsions

  3. Breaking of the emulsions and hybridization to fluorescent probes

  4. Flow cytometry readout

Click to Play Video

For oncologists interested in learning more about the benefits of blood-based biopsies with OncoBEAM, visit www.Oncobeam.com